Tag: amicus therapeutics

January 1, 2019

An Investor’s Guide to Clinical Trials

Clinical trials can be one of the more challenging US Food and Drug Administration processes to understand, but grasping the...
December 20, 2018

Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease

Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced...
September 10, 2018

Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease

Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced...
March 23, 2018

Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan

Amicus Therapeutics (Nasdaq:FOLD) announced today that Japan’s Ministry of Health, Labour and Welfare has approved the oral small molecule pharmacological chaperone Galafold capsules...
February 28, 2018

Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates

Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced...
February 16, 2018

Amicus Therapeutics Prices Underwritten Offering of Common Stock

Amicus Therapeutics (Nasdaq:FOLD) announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share....
February 15, 2018

Amicus Therapeutics Announces Public Offering of Common Stock

Amicus Therapeutics (Nasdaq:FOLD) announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities...